Found: 17
Select item for more details and to access through your institution.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1641, doi. 10.1007/s10637-021-01152-z
- By:
- Publication type:
- Article
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
- Published in:
- BMC Biology, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12915-024-01839-8
- By:
- Publication type:
- Article
Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 14, p. 11570, doi. 10.3390/ijms241411570
- By:
- Publication type:
- Article
Hyperprogression under Immunotherapy.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 11, p. 2674, doi. 10.3390/ijms20112674
- By:
- Publication type:
- Article
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE.
- Published in:
- Cancer Reports, 2023, v. 6, n. 5, p. 1, doi. 10.1002/cnr2.1804
- By:
- Publication type:
- Article
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
- Published in:
- BioDrugs, 2020, v. 34, n. 4, p. 463, doi. 10.1007/s40259-020-00425-y
- By:
- Publication type:
- Article
Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 16, p. 3001, doi. 10.1002/1878-0261.13219
- By:
- Publication type:
- Article
Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial.
- Published in:
- Molecular Oncology, 2021, v. 15, n. 1, p. 104, doi. 10.1002/1878-0261.12776
- By:
- Publication type:
- Article
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 431, doi. 10.1177/1758834017708742
- By:
- Publication type:
- Article
Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-86816-9
- By:
- Publication type:
- Article
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
- Published in:
- Drugs in R&D, 2021, v. 21, n. 4, p. 399, doi. 10.1007/s40268-021-00362-3
- By:
- Publication type:
- Article
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
- Published in:
- JNCI Cancer Spectrum, 2019, v. 3, n. 4, p. N.PAG, doi. 10.1093/jncics/pkz055
- By:
- Publication type:
- Article
HDAC Inhibition to Prime Immune Checkpoint Inhibitors.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 66, doi. 10.3390/cancers14010066
- By:
- Publication type:
- Article
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2573, doi. 10.3390/cancers13112573
- By:
- Publication type:
- Article
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1699, doi. 10.3390/cancers11111699
- By:
- Publication type:
- Article
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 55, doi. 10.1111/cts.13002
- By:
- Publication type:
- Article